Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2018

Open Access 01-12-2018 | Primary Research

Tumor-suppressor role of miR-139-5p in endometrial cancer

Authors: JinHui Liu, ChunYu Li, Yi Jiang, YiCong Wan, ShuLin Zhou, WenJun Cheng

Published in: Cancer Cell International | Issue 1/2018

Login to get access

Abstract

Background

Endometrial cancer (EC) is the fourth most common malignancy of the female genital tract worldwide. MicroRNAs are important gene regulators with critical roles in diverse biological processes, including tumorigenesis. Several study’s show that miR-139-5p is involved in the tumorigenesis and metastasis of various cancers. However, its expression and potential biologic role in endometrial cancer remain to be determined. This study aimed to investigate the miR-139-5p expression and to analyze its function and underlying molecular mechanism in endometrial cancer.

Methods

Expression of miR-139-5p was measured using qRT-PCR. The expression of HOXA10 was detected by Immunofluorescence staining in endometrial cancer tissues and adjacent normal tissues. CCK-8 and colony formation assays were used to assess the effect of miR-139-5p on ECC1 and Ishikawa cell line proliferation. Transwell migration assay was used to study the effect of miR-139-5p on EC cell migration. Luciferase reporter assay and western blot were used to confirm targeting of HOXA10 by miR-139-5p.

Result

We demonstrated that miR-139-5p was down-regulated in human endometrial cancer compared to their matched adjacent non-tumor tissues. Overexpressed miR-139-5p significantly inhibited endometrial cancer cell viability and migration. Computational algorithm in combination with dual luciferase reporter assays identified HOXA10 as the target of miR-139-5p. HOXA10 expression was downregulated in endometrial cancer cells after miR-139-5p overexpression. The expression level of HOXA10 was significantly increased in endometrial cancer tissues, which was inversely correlated with miR-139-5p expression in clinical endometrial cancer tissues.

Conclusion

These findings indicate that miR-139-5p targets the HOXA10 transcript and suppresses endometrial cancer cell growth and migration, suggesting that miR-139-5p acts as a tumor suppressive role in human endometrial cancer pathogenesis.
Appendix
Available only for authorised users
Literature
1.
Brooks N, Pouniotis DS. Immunomodulation in endometrial cancer. Int J Gynecol Cancer. 2009;19(19):734–40.CrossRefPubMed
2.
Banno K, Nogami Y, Kisu I, Yanokura M, Umene K, Masuda K, Kobayashi Y, Yamagami W, Susumu N, Aoki D. Candidate biomarkers for genetic and clinicopathological diagnosis of endometrial cancer. Int J Mol Sci. 2013;14(6):12123–37.CrossRefPubMedPubMedCentral
3.
Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS. Emerging therapeutic targets in endometrial cancer. Clin Oncol. 2011;8(5):261–71.
4.
Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification and targeted therapies. Cancer Control. 2009;16(1):8–13.CrossRefPubMed
5.
Wilczynski M, Danielska J, Dzieniecka M, Szymanska B, Wojciechowski M, Malinowski A. Prognostic and Clinical Significance of miRNA-205 in endometrioid endometrial cancer. Plos One. 2016;11(10):e0164687.CrossRefPubMedPubMedCentral
6.
Banno K, Yanokura M, Kisu I, Yamagami W, Susumu N, Aoki D. MicroRNAs in endometrial cancer. Int J Clin Oncol. 2013;18(2):186–92.CrossRefPubMed
7.
Chen H, Fan Y, Xu W, Chen J, Xu C, Wei X, Fang D, Feng Y. miR-10b inhibits apoptosis and promotes proliferation and invasion of endometrial cancer cells via targeting HOXB3. Cancer Biother Radiopharm. 2016;31(6):225–31.CrossRefPubMed
8.
Yue Z, Shen JJ, Huang QT, Qin YF, Li XN, Liu GB. [MiR-135b promotes proliferation of endometrial carcinoma cells by targeting FOXO1]. J South Med Univ. 2016;36(5):675.
9.
Sun X, Cui M, Zhang A, Tong L, Wang K, Kai L, Xue W, Sun Z, Zhang H. MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist. J Exp Clin Cancer Res. 2016;35(1):1–9.CrossRef
10.
Zhao X, Zhu D, Lu C, Yan D, Li L, Chen Z. MicroRNA-126 inhibits the migration and invasion of endometrial cancer cells by targeting insulin receptor substrate 1. Oncol Lett. 2016;11(2):85.
11.
Ping L, Chao W, Ma C, Wu Q, Zhang W, Lao G. MicroRNA-23a regulates epithelial-to-mesenchymal transition in endometrial endometrioid adenocarcinoma by targeting SMAD3. Cancer Cell Int. 2016;16(1):67.CrossRef
12.
Ran X, Yang J, Liu C, Zhou P, Xiao L, Zhang K. MiR-218 inhibits HMGB1-mediated autophagy in endometrial carcinoma cells during chemotherapy. Int J Clin Exp Pathol. 2015;8(6):6617–26.PubMedPubMedCentral
13.
Sun KX, Chen Y, Chen S, Liu BL, Feng MX, Zong ZH, Zhao Y. The correlation between microRNA490-3p and TGFα in endometrial carcinoma tumorigenesis and progression. Oncotarget. 2016;7(8):9236–49.PubMedPubMedCentral
14.
Liu R, Yang M, Meng Y, Liao J, Sheng J, Pu Y, Yin L, Sun JK. Tumor-suppressive function of miR-139-5p in esophageal squamous cell carcinoma. PLoS ONE. 2013;8(10):65.
15.
Qiu G, Lin Y, Zhang H, Wu D. miR-139-5p inhibits epithelial–mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2. Biochem Biophys Res Commun. 2015;463(3):315–21.CrossRefPubMed
16.
Sun C, Sang M, Li S, Sun X, Yang C, Xi Y, Wang L, Zhang F, Bi Y, Fu Y. Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget. 2015;6(37):39756–92.CrossRefPubMedPubMedCentral
17.
Zou F, Mao R, Yang L, Lin S, Lei K, Zheng Y, Ding Y, Zhang P, Cai G, Liang X. Targeted deletion of miR-139-5p activates MAPK, NF-κB and STAT3 signaling and promotes intestinal inflammation and colorectal cancer. Febs J. 2016;283(8):1438.CrossRefPubMed
18.
Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du Y, Luo X, Zheng F, Liu R, Zhang H. miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer. 2012;12(1):111.CrossRefPubMedPubMedCentral
19.
Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, Lawrence HJ, Largman C, Humphries RK. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol. 1997;17(1):495–505.CrossRefPubMedPubMedCentral
20.
Chu MC, Selam FB, Taylor HS. HOXA10 regulates p53 expression and matrigel invasion in human breast cancer cells. Cancer Biol Ther. 2004;3(6):568–72.CrossRefPubMed
21.
Kim JW, Kim JY, Kim JE, Kim SK, Chung HT, Park CK. HOXA10 is associated with temozolomide resistance through regulation of the homologous recombinant DNA repair pathway in glioblastoma cell lines. Genes Cancer. 2014;5(5–6):165–74.PubMedPubMedCentral
22.
Zhang L, Wan Y, Jiang Y, Ma J, Liu J, Tang W, Wang X, Cheng W. Upregulation HOXA10 homeobox gene in endometrial cancer: role in cell cycle regulation. Med Oncol. 2014;31(7):1–10.
23.
Ma J, Li D, Kong FF, Yang D, Yang H, Ma XX. miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development. J Exp Clin Cancer Res. 2018:37(1):19.CrossRefPubMedPubMedCentral
24.
Yan C, Jiang Y, Wan Y, Zhang L, Liu J, Zhou S, Cheng W. Long noncoding RNA NBAT-1 suppresses tumorigenesis and predicts favorable prognosis in ovarian cancer. Onco Ther. 1993;2017:10.
25.
Yonemori M, Seki N, Yoshino H, Matsushita R, Miyamoto K, Nakagawa M, Enokida H. Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. Cancer Sci. 2016;107(9):1233–42.CrossRefPubMedPubMedCentral
26.
Bei L, Lu Y, Bellis SL, Zhou W, Horvath E, Eklund EA. Identification of a HoxA10 activation domain necessary for transcription of the gene encoding beta3 integrin during myeloid differentiation. J Biol Chem. 2007;282(23):687–94.CrossRef
27.
Ford HL. Homeobox genes: a link between development, cell cycle, and cancer? Cell Biol Int. 1998;22(6):397–400.CrossRefPubMed
28.
Yoshida H, Broaddus R, Cheng W, Xie SS, Naora H. Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelial–mesenchymal transition. Can Res. 2006;66(2):889–97.CrossRef
29.
Carrera M, Bitu CC, de Oliveira CE, Cervigne NK, Graner E, Manninen A, Salo T, Coletta RD. HOXA10 controls proliferation, migration and invasion in oral squamous cell carcinoma. Int J Clin Exp Pathol. 2014;8(4):3613–23.
30.
Han Y, Lu S, Wen YG, Yu FD, Zhu XW, Qiu GQ, Tang HM, Peng ZH, Zhou CZ. Overexpression of HOXA10 promotes gastric cancer cells proliferation and HOXA10(+)/CD44(+) is potential prognostic biomarker for gastric cancer. Eur J Cell Biol. 2015;94(12):642–52.CrossRefPubMed
31.
Tang W, Jiang Y, Mu X, Xu L, Cheng W, Wang X. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression. Cell Signal. 2014;26(7):1420–6.CrossRefPubMed
Metadata
Title
Tumor-suppressor role of miR-139-5p in endometrial cancer
Authors
JinHui Liu
ChunYu Li
Yi Jiang
YiCong Wan
ShuLin Zhou
WenJun Cheng
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2018
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-018-0545-8

Other articles of this Issue 1/2018

Cancer Cell International 1/2018 Go to the issue

Primary Research

Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy

Primary research

Antitumor activity of arsenite in combination with tetrandrine against human breast cancer cell line MDA-MB-231 in vitro and in vivo

Primary research

Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin

Primary research

Cellular and clinicopathological features of the IL-33/ST2 axis in human esophageal squamous cell carcinomas

Primary research

APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study

Primary Research

A cross-talk between integrin β4 and epidermal growth factor receptor induces gefitinib chemoresistance to gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits